

Liquid Formulation of Lactoferrin as a Model Glycoprotein

Chang Hoon Shin¹, Tae Ho Byun², Chan-Wha Kim^{1*}

¹School of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea

TEL: +82-2-3290-3939, FAX: +82-2-3290-3957

E-mail: cwkim@korea.ac.kr

²Samsung Fine Chemical CO., LTD R&D Center, Suwon 440-746, Korea

TEL: +82-31-299-6448, FAX: +82-31-299-6449

The aim of this study is to develop a liquid formulation of Interferon-beta using Lactoferrin as a model protein. Interferon-beta (IFN- β) is used to treat multiple sclerosis (MS). The lyophilized formulation of IFN- β commonly contains complex organic excipients and stabilizers such as nonionic surface active agents, various sugars, organic polysols and human serum albumin (HSA). However, the use of HSA has drawbacks. HSA from human blood has a potential to introduce virus contamination such as HIV, HBV, HCV. Therefore, we selected amino acids as a stabilizing agent instead of HSA. Amino acids are the most preferred stabilizing agent for the present research. In this study, we used Lactoferrin as a model glycoprotein instead of IFN- β since Lactoferrin has a pI (8.0-8.2) similar to that of IFN- β . In addition, it has the possible immunomodulatory activity. Analyses were performed using reverse-phased high-performance liquid chromatography and UV spectrometry.

References

1. Phillips JT, Rice G, Frohman E, Vande Gaer L, Scott T, A multicenter, open-label, phase II study of the immunogenicity and safety of a new pre-filled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. (2004), *Clinical Therapies*, 26(4), 511-21

2. Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Wiegmans FC, Harmsen MC, Molema G, Meijer DK., Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. (2004), *Antiviral Research*, 63(3), 197-208